

Scientific Program

Monday 30 October 2017

07:00-17:00	Registration desk open Level 5 foyer, The Pharmacy Australia Centre of Excellence (PACE)	
08:30-08:45	Conference opening	
	Room: PACE Auditorium	
08:45-09:45	Welcome ceremony Jesper Hallas, President, International Society for Pharmacoepidemiology; University of Southern Denmark, Denmark Samantha Hollingworth, Senior Lecturer, School of Pharmacy, The University of Queensland, Australia	
	Plenary address Chair: Sallie Pearson, Centre for Big Data Research in Health, University of New South Wales, Australia False dichotomies and health intervention research designs: Randomized trials are not always the answer - 100 Stephen Soumerai, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA	
09:45-10:10	Morning tea and poster viewing	
10:15-11:45	Symposium 1: PRECISION MEDICINE AND AUSTRALASIAN DATABASES IN PHARMACOEPIDEMIOLOGY STUDIES	Oral presentation session 1: MANAGING CARDIOVASCULAR RISKS
	Moderated by: Geoffrey Liu, University of Toronto, Canada Samantha Hollingworth, The University of Queensland, Australia	Moderated by: Judith Coombes, The University of Queensland, Australia Vincent Lo Re, University of Pennsylvania, USA
	Room: PACE Auditorium	Room: Seminar rooms 5034-5035
10:15-10:30	What is Precision Medicine? And why should it matter to pharmacoepidemiologists globally? Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada	Comparative effectiveness and safety of low and high strength novel oral anticoagulants: A propensity-score study with sequential cohort design - 101 Emmae Ramsay, The University of South Australia, Australia
10:30-10:45	Integrating biological samples and associated data into large Asian databases: A Primer Wei Zhou, Merck Center for Observational and Real World Evidence, USA	Signal evaluation of adverse drug reaction caused by non-vitamin K dependent oral anticoagulants (NOACs) in Korean adverse drug reporting system (KAERS) database - 102 Young-Jin Ko, Seoul National University College of Medicine, South Korea
10:45-11:00	Pharmacogenomics: Study design and analytical approaches Stuart MacGregor, The University of Queensland, Australia	The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation - 103 Laura Fanning, Monash University, Australia
11:00-11:15	The landscape of observational drug databases in Australia and readiness to capture biospecimen elements Samantha Hollingworth, The University of Queensland, Australia	Aspirin reduces the risk of out-of-hospital cardiac arrest with ventricular tachycardia/ventricular fibrillation in patients with coronary artery disease - 104 Alfi Yasmina, Lambung Mangkurat University, Indonesia
11:15-11:30	Panel discussion: Benefits and challenges of integrating precision medicine into Australasian pharmacoepidemiology research	Hospital admissions due to dysglycaemia and antidiabetic medications prescriptions in England and Wales: An observational study - 105 Abdallah Naser, UCL School of Pharmacy, United Kingdom
11:30-11:45	Moderated by: Sallie Pearson, Centre for Big Data Research in Health, University of New South Wales, Australia Panellists: Geoffrey Liu, Wei Zhou, Stuart MacGregor, Samantha Hollingworth	Cardiovascular safety of glucose lowering drugs in patients with type 2 diabetes mellitus and cardiovascular disease: A network meta-analysis - 106 Guangyao Li, Peking University, China
11:45-12:40	Lunch and poster discussions	
12:45-13:30	Plenary address	
	Chair: Debra Rowett, Drug and Therapeutics Information Service, Australia	
	Room: PACE Auditorium Beyond symptom control in ADHD – the contribution of pharmacoepidemiology in addressing benefit and risk - 107 Ian Chi Kei Wong, UCL School of Pharmacy, United Kingdom	

13:30-15:00	Oral presentation session 2: GROWING OLDER WITH PSYCHOACTIVE MEDICINES	Oral presentation session 3: METHODS AND GOOD PUBLIC POLICY
	Moderated by: Samantha Hollingworth, The University of Queensland, Australia Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada	Moderated by: Byung-Joo Park, Seoul National University College of Medicine, South Korea John McEwen, Therapeutic Goods Administration, Australia
	Room: Seminar rooms 5034-5035	Room: PACE Auditorium
13:30-13:45	Doubt of association between the proton pump inhibitors and the risk of dementia: Signal detection using prescription sequence symmetry analysis - 108 Sun-Kyeong Park, Sungkyunkwan University, South Korea	The discrepancy between Mantel-Haenszel and conditional logistic estimators in a case-crossover study: An exploratory study followed by a simulation study - 114 Kiyoshi Kubota, NPO Drug Safety Research Unit, Japan
13:45-14:00	Risk of dementia in proton pump inhibitors users as compared with histamine-2 receptor antagonist: Propensity-score matched cohort study in Korea - 109 Sun-Kyeong Park, Sungkyunkwan University, South Korea	Data linkage and patients' perspective: Insights from a national survey in the United States - 115 Soko Setoguchi, Rutgers University, United States
14:00-14:15	Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies - 110 Salman Hussain, Hamdard University, India	Investigating use of administrative data sets for safety signal verification in the setting of therapeutic goods regulation in Australia - 116 Margaret Wilson, Therapeutic Goods Administration, Australia
14:15-14:30	Incidence and risk factors of mortality among schizophrenia and antipsychotic-treated patients in Taiwan - 111 Darmendra Ramcharran, Janssen Research and Development Global Epidemiology, United States	Development of a risk proportionality framework for the selection of risk minimisation interventions in Asia: Results of a pre-Delphi panel - 117 Yola Moride, Universite de Montreal, Canada
14:30-14:45	A group based trajectory analysis of longitudinal psychotropic agents use and associated adverse outcomes in the elderly - 112 Shih-Tsung Huang, National Taiwan University, Taiwan	But what is the cost? Application of pharmacoepidemiological methods assist payers in quantifying uncertainties in cost of medicines - 118 Maxine Freeman-Robinson, The University of South Australia, Australia
14:45-15:00	Evaluating the impact of two Pharmaceutical Benefits Scheme (PBS) restriction changes on quetiapine use: An interrupted time series analysis - 113 Jonathan Brett, Centre for Big Data Research in Health, Australia	The predictive validity for mortality of a prescription-based comorbidity index: An updated Rx-Risk index - 119 Mhairi Kerr, The University of South Australia, Australia
15:00-15:25	Afternoon tea and poster viewing	
15:30-17:00	Symposium 2: VALIDATION OF LARGE ADMINISTRATIVE DATABASES IN ASIA: METHODOLOGICAL AND PRACTICAL CHALLENGES	Oral presentation session 4: ISSUES OF SAFETY AND QUALITY
	Room: PACE Auditorium Moderated by: Kiyoshi Kubota, NPO Drug Safety Research Unit, Japan Cynthia de Luise, Worldwide Safety and Regulatory, Pfizer, USA	Room: Seminar rooms 5034-5035 Moderated by: Christine Staatz, The University of Queensland, Australia Yea-Huei Kao Yang, National Cheng Kung University, Taiwan
15:30-15:45	Validation studies of claims data in Japan – An overview and case study on the accuracy of Japanese claims data in identifying breast cancer Izumi Sato, Kyoto University; The Keihanshin Consortium for Fostering the Next Generation of Global Leaders in Research, Japan	Drug-induced anaphylaxis in the hospital setting in Beijing, China: A retrospective analysis of the Beijing Pharmacovigilance Database - 120 Xiaotong Li, Peking University Third Hospital, China
15:45-16:00		Factors associated with intravenous and repeated use of epinephrine for drug-induced anaphylaxis: A retrospective analysis of the Beijing Pharmacovigilance Database - 121 Ying Zhao, Peking University Health Science Center, China
16:00-16:15	Taiwan experience and future developments Arnold Chan, National Taiwan University, Taiwan	The association between parkinsonism and drugs possibly related with parkinsonism in Korea: A population-based case-control study - 122 Siin Kim, Pusan National University, South Korea
16:15-16:30	Validation in Hong Kong - challenges, opportunities and needs compared to other data sources Ian C K Wong, University College London, United Kingdom; University of Hong Kong, Hong Kong	Adverse effects of β-blockers in older nursing home residents after acute myocardial infarction - 123 Andrew Zullo, Brown University School of Public Health, United States
16:30-16:45	Panel discussion: Issues and themes on conducting validation studies in Asia Izumi Sato, Arnold Chan, Ian C K Wong and Soko Setoguchi, Rutgers University, USA	Active surveillance systems for vaccine safety: A systematic review of the surveillance models - 124 Ting Cai, Peking University, China
16:45-17:00		What do consumers want to know about their medicines? Consumer queries compared to medicines use? - 125 Treasure McGuire, The University of Queensland, Australia
17:00	End of day 1	

Monday 30 October 2017 continued

17:00-18:00	Medicines Use Research Australia (MURA) Session: DUR - INFORMING AND EVALUATING POLICY Room: Seminar rooms 5034-5035 Alicia Seagrave, Drug Utilization Sub-Committee, Australian Department of Health, Australia Sallie Pearson, Centre for Big Data Research in Health, University of New South Wales, Australia
19:00-22:00	Conference dinner South Bank Surf Club, 30aa Stanley Plaza, South Bank Parklands

Tuesday 31 October 2017

08:30-16:30	Registration desk open Level 5 foyer, The Pharmacy Australia Centre of Excellence (PACE)	
08:00-09:00	Asian Pharmacoepidemiology Network (AsPEN) Session: INTRODUCTION TO ASIAN PHARMACOEPIDEMOLOGY Room: PACE Auditorium AsPEN introduction and our achievements so far Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan Current and ongoing studies Kenneth Mann, University of Hong Kong, Hong Kong Challenges and future directions for AsPEN Nicole Pratt, The University of South Australia, Australia Interactive discussion	
09:00-10:30	Oral presentation session 5: PAEDIATRIC ISSUES, PAIN AND OPIOID USE	Oral Presentation session 6: HEALTHY PREGNANCIES AND NEOPLASTIC ISSUES
	Moderated by: Adam LaCaze, The University of Queensland, Australia Soko Setoguchi, Rutgers University, United States	Moderated by: Genevieve Gabb, Royal Adelaide Hospital, Australia Siyan Zhan, Peking University, China
	Room: PACE Auditorium	Room: Seminar rooms 5034-5035
09:00-09:15	Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. - 126 Kenneth Man, University of Hong Kong, Hong Kong	Exposure to teratogenic medicines before, during and after pregnancy in New South Wales, Australia - 132 Smriti Raichand, University of New South Wales, Australia
09:15-09:30	Metabolic side effects of antipsychotics in children, adolescents and young adults – an international multi-database pharmacoepidemiologic study - 127 Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan	Risk of adverse perinatal outcomes associated with early pregnancy use of renin-angiotensin system blockers for the management of chronic hypertension - 133 Bilal Ahmed, Centre for Big Data Research in Health, Australia
09:30-09:45	An ecological study of the extent and factors associated with the use of fentanyl across Australia - 128 Natasa Gisev, University of New South Wales, Australia	Safety of varenicline versus prescription nicotine patches during pregnancy: Findings from Smoking MUMS (Maternal Use of Medications and Safety) Study - 134 Duong Tran, Centre for Big Data Research in Health, Australia
09:45-10:00	Predictors of persistent use of prescription opioid analgesics among people without cancer - 129 Samanta Lalic, Monash University, Australia	Patterns of care for long-term surviving trastuzumab-treated patients with HER2-positive metastatic breast cancer (HER2+MBC): An Australian whole-of-population cohort study - 135 Benjamin Daniels, University of New South Wales, Australia
10:00-10:15	Change in utilisation of long-acting oxycodone after introduction of oxycodone/naloxone in Australia: A population-based study - 130 Andrea Schaffer, Centre for Big Data Research in Health, Australia	Incidence of comorbidities in women treated with tamoxifen or an aromatase inhibitor: An Australian population based cohort study - 136 Huah Shin Ng, The University of South Australia, Australia
10:15-10:30	Quantifying the extent that PBS/RBS claims data under-estimate opioid analgesic utilisation in Australia - 131 Natasa Gisev, University of New South Wales, Australia	Statins use and the risk of prostate cancer: A nationwide population-based cohort study - 137 Wei Ho, National Taiwan University, Taiwan
10:30-10:55	Morning tea and poster viewing	

11:00-12:30	Poster discussions with all presenters AND spotlight poster sessions	
11:00-11:30	Session 1: BLEEDING ISSUES AND NSAIDs	
	Moderated by: Judith Coombes, The University of Queensland, Australia	
	Bleeding-related hospital admissions and 30-day readmissions with dabigatran versus warfarin in patients with nonvalvular atrial fibrillation - 201 Wallis CY Lau, The University of Hong Kong, Hong Kong	
	'Real-world' hemorrhagic rates for antithrombotics using a self-controlled case series design - 202 Prasad Nishtala, University of Otago, Taiwan	
	High-risk non-steroidal anti-inflammatory drug (NSAID) prescribing in primary care: Results from a developing nation - 203 Mei Fong Lim, Ministry of Health Malaysia, Malaysia	
	Non-steroidal anti-inflammatory drugs and risk of first hospitalization for heart failure: A population-based case-crossover study - 204 Sung-Po Huang, National Taiwan University, Taiwan	
11:30-12:00	Session 2: CARDIOVASCULAR ISSUES AND DIABETES	
	Moderated by: John McEwen, University of Canberra, Australia	
	Statin use and risk of new-onset diabetes in hypertensive patients: A population-based retrospective cohort study in mainland China - 206 Hailong Li, Peking University, China and Siyan Zhan, Peking University, China	
	Selective prescribing and estimation of risks and benefits of statins in aged care services - 207 Jenni Ilomaki, Monash University, Australia	
	Effects of cilostazol and renin-angiotensin-aldosterone system (RAS) blockers on the progression of renal disease in diabetic patients - 208 Sukhyang Lee, Ajou University, South Korea	
	Impacts of FDA safety warning and introduction of new class medications on treatment outcomes in patients with type 2 diabetes - 209 Kai-Cheng Chang, Linkou Chang Gung Memorial Hospital, Taiwan	
12:00-12:30	Session 3: POT-POURRI	
	Moderated by: Richard Hill, Therapeutic Goods Administration, Department of Health, Australia	
	Comparing strategies to monitor for a potential association between teriparatide and adult osteosarcoma - 211 Kirk Midkiff, RTI Health Solutions, USA	
	Design considerations for developing smartphone app-based side effect monitoring systems for patients taking oral anticancer medications - 212 Eskinder Eshetu Ali, National University of Singapore, Singapore	
	Use of epinephrine in patients with drug-induced anaphylaxis: An analysis of the Beijing Pharmacovigilance Database - 213 Ying Zhao, Peking University, China	
	Sequence symmetry analysis of Pharmaceutical Benefits Scheme data for signal detection in the setting of therapeutic goods regulation in Australia - 214 Clare King, Therapeutic Goods Administration, Department of Health Australia, Australia	
12:30-13:25	Lunch and poster viewing	
13:30-15:00	Symposium 3: POST-APPROVAL SAFETY MONITORING AND ACTIVE SURVEILLANCE: EASTERN ASIA'S PERSPECTIVE	Symposium 4: A NATIONAL APPROACH OF PHARMACOEPIDEMIOLOGIC RESEARCH: THE CANADIAN NETWORK FOR OBSERVATIONAL DRUG EFFECT STUDIES (CNODES)
	Moderated by: Arnold Chan, National Taiwan University	Moderated by: David Henry, Bond University, Australia
	Room: Seminar rooms 5034-5035	Room: PACE Auditorium
	Australia - history, current status, future initiatives John McEwen, University of Canberra; Therapeutic Goods Administration, Australia	Introduction: Mission, objectives, organisation of CNODES Adrian Levy, Dalhousie University, Canada
	Post-approval safety surveillance in Japan: Regulation changes in 2017 and the future Shinichi Matsuda, Chugai Pharmaceutical Co, Japan	CNODES methods and training activities Robert Platt, McGill University, Canada
	Development of drug safety management system in Korea Byung Joo Park, Seoul National University, Korea	Methods and results of key CNODES studies Kristian Filion, McGill University, Canada
	Panel discussion John McEwen, Shinichi Matsuda, Byung Joo Park, and Solomon Iyasu, Merck Research laboratories, USA; Siyan Zhan, Peking University Health Science Center, China	CNODES knowledge translation and dissemination activities Adrian Levy, Dalhousie University, Canada
		Conclusion/Q&A Adrian Levy, Dalhousie University, Canada
15:00-15:15	Afternoon tea and poster viewing	
15:20-16:05	Plenary address	
	Chair: Nicole Pratt, University of South Australia, Australia	
	Room: PACE Auditorium	
	Pharmacoepidemiology in Nordic countries, a fairy tale? - 138 Jesper Hallas, President, International Society for Pharmacoepidemiology; University of Southern Denmark, Denmark	
16:05-16:30	Closing and award ceremony	